These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15645669)

  • 1. Current and future approaches to ensure the viral safety of biopharmaceuticals.
    Brorson K; Norling L; Hamilton E; Lute S; Lee K; Curtis S; Xu Y
    Dev Biol (Basel); 2004; 118():17-29. PubMed ID: 15645669
    [No Abstract]   [Full Text] [Related]  

  • 2. An industry perspective on plasma-derived products.
    von Hoegen I
    Dev Biol (Basel); 2004; 118():31-5. PubMed ID: 15645670
    [No Abstract]   [Full Text] [Related]  

  • 3. Future directions for ensuring viral safety of biopharmaceuticals.
    Trent DW
    Dev Biol Stand; 1996; 88():333-5. PubMed ID: 9119159
    [No Abstract]   [Full Text] [Related]  

  • 4. Viral safety evaluation of plasma-derived therapeutic products.
    Farshid M
    Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction to the issues: new potential contaminants and other exogenous agents.
    Albrecht P
    Dev Biol Stand; 1992; 76():255-8. PubMed ID: 1478344
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction to the issues: viral vectors and potential problems in their use.
    Klinman DM
    Dev Biol Stand; 1992; 76():299-300. PubMed ID: 1478347
    [No Abstract]   [Full Text] [Related]  

  • 7. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in biological source material.
    Robertson JS
    Biologicals; 2006 Mar; 34(1):61-3. PubMed ID: 16330224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 10. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative NAT for pathogen inactivation verification.
    McKenney K; Gillmeister L; Marlowe K; Armistead D; Burgess W; Drohan W
    Dev Biol (Basel); 2004; 118():81-8. PubMed ID: 15645676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
    Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of biological products prepared from mammalian cell culture. Testing source materials.
    Dev Biol Stand; 1998; 93():131-3. PubMed ID: 9737390
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of biological products prepared from mammalian cell culture. Detecting viruses in cell banks.
    Dev Biol Stand; 1998; 93():129. PubMed ID: 9737388
    [No Abstract]   [Full Text] [Related]  

  • 15. Viral safety evaluation of biopharmaceuticals and homoeopathic preparations of human or animal origin.
    Immelmann A
    Pharmeur Sci Notes; 2006 Aug; 2006(1):41-5. PubMed ID: 17694646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of anti-viral filters.
    Hughes B; Bradburne A; Sheppard A; Young D
    Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal virus contaminants of biotechnology products.
    Onions D
    Dev Biol (Basel); 2004; 118():155-63. PubMed ID: 15645686
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.